Egg substitute, without cholesterol ( DrugBank: Cholesterol, Egg )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 310 | Congenital anomalies syndrome | 1 |
310. Congenital anomalies syndrome
Clinical trials : 10 / Drugs : 18 - (DrugBank : 10) / Drug target genes : 3 - Drug target pathways : 7
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT00114634 (ClinicalTrials.gov) | June 2005 | 15/6/2005 | Short-term Behavioral Effects of Cholesterol Therapy in Smith-Lemli-Opitz Syndrome | Short-Term Behavioral Effects of Cholesterol Therapy in Smith-Lemli-Opitz Syndrome | Smith-Lemli-Opitz Syndrome | Dietary Supplement: Egg yolk preparation with cholesterol;Dietary Supplement: Egg substitute, without cholesterol | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | NULL | Completed | 4 Years | 17 Years | All | 13 | Phase 2 | United States |